Nicox: Bausch and Lomb entering phase III with latanoprostène bunod

BUY, Fair Value EUR3.7 vs. EUR3.2 (+12%)

News published on January Tuesday 29, 2013
Share on
NicOx and Bausch and Lomb (B+L) announced today the start of a phase III programme for latanoprostène bunod (ex NCX116 and BOL-303259-X). Two phase IIIs, APOLLO and LUNAR, will enroll 800 patients and compare intro ocular pressure (IOP) reduction and the safety profile of once-daily latanoprostène bunod versus twice daily Timolol. We believe that the study design looks favourable as the investigational compound will be compared with Timolol, a pretty old drug, whereas a study versus Xalatan (Pfizer), the active component of latanoprostène bunod, could have been more challenging.

Full report available to subscribers
Please contact marketing@bryangarnier.fr

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities